S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Price, News & Analysis

$0.68
-0.01 (-1.45%)
(As of 03/18/2024 ET)
Today's Range
$0.64
$0.72
50-Day Range
$0.55
$0.90
52-Week Range
$0.49
$3.67
Volume
86,392 shs
Average Volume
248,064 shs
Market Capitalization
$18.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Xilio Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.13mentions of Xilio Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1,832 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.76) to ($1.89) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.77 out of 5 stars

Medical Sector

471st out of 947 stocks

Pharmaceutical Preparations Industry

222nd out of 435 stocks

XLO stock logo

About Xilio Therapeutics Stock (NASDAQ:XLO)

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

XLO Stock Price History

XLO Stock News Headlines

They said crypto was dead. It went up 100X.
Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.
Xilio Therapeutics Inc XLO
Like Tiny Crypto Retirement Funds
The crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds.
Xilio Therapeutics GAAP EPS of -$0.61
Xilio Therapeutics Appoints Katarina Luptakova As CMO
Q2 2023 Xilio Therapeutics Inc Earnings Call
XLO - Xilio Therapeutics, Inc.
See More Headlines
Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/01/2021
Today
3/18/2024
Next Earnings (Estimated)
3/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XLO
Fax
N/A
Employees
81
Year Founded
N/A

Profitability

Net Income
$-88,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.85 per share

Miscellaneous

Free Float
26,275,000
Market Cap
$18.69 million
Optionable
Not Optionable
Beta
-0.32
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Rene Russo BCPS (Age 49)
    Pharm.D., President, CEO & Director
    Comp: $888.49k
  • Mr. Kevin M. Brennan (Age 54)
    Senior VP of Finance & Accounting
  • Mr. Christopher Frankenfield
    Chief Operating Officer
  • Dr. Uli Bialucha Ph.D.
    Chief Scientific Officer
  • Julissa Viana
    Vice President of Corporate Communications
  • Ms. Stacey J. Davis
    Chief Business Officer
  • Dr. Katarina Luptakova M.D.
    Chief Medical Officer
  • Dr. Scott Coleman Ph.D.
    Chief Development Officer

XLO Stock Analysis - Frequently Asked Questions

Should I buy or sell Xilio Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XLO shares.
View XLO analyst ratings
or view top-rated stocks.

How have XLO shares performed in 2024?

Xilio Therapeutics' stock was trading at $0.55 at the beginning of 2024. Since then, XLO stock has increased by 23.4% and is now trading at $0.6787.
View the best growth stocks for 2024 here
.

Are investors shorting Xilio Therapeutics?

Xilio Therapeutics saw a decrease in short interest in February. As of February 29th, there was short interest totaling 21,200 shares, a decrease of 37.3% from the February 14th total of 33,800 shares. Based on an average daily volume of 222,400 shares, the short-interest ratio is presently 0.1 days. Approximately 0.2% of the company's stock are sold short.
View Xilio Therapeutics' Short Interest
.

When is Xilio Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our XLO earnings forecast
.

How were Xilio Therapeutics' earnings last quarter?

Xilio Therapeutics, Inc. (NASDAQ:XLO) announced its earnings results on Wednesday, December, 1st. The company reported ($21.27) earnings per share for the quarter, missing analysts' consensus estimates of ($1.60) by $19.67.

When did Xilio Therapeutics IPO?

(XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.

Who are Xilio Therapeutics' major shareholders?

Xilio Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Octagon Capital Advisors LP (6.48%), Bridgeway Capital Management LLC (0.56%) and Citadel Advisors LLC (0.19%). Insiders that own company stock include Bain Capital Life Sciences Inv, Rock Springs Capital Managemen and Venture Fund Xi LP Atlas.
View institutional ownership trends
.

How do I buy shares of Xilio Therapeutics?

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XLO) was last updated on 3/18/2024 by MarketBeat.com Staff

From Our Partners